About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, May 21st, 2014

The QualityStocks
Daily Stock List

graphic
graphic

HyperSolar, Inc. (HYSR)

AimHighProfits reported recently on HyperSolar, Inc. (HYSR), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Trading on the OTC Markets’ OTCQB, HyperSolar, Inc. is developing an innovative, low cost technology to make renewable hydrogen using sunlight and any source of water. This includes seawater and wastewater. The Company’s solution is the HyperSolar H2Generator™. Its solar hydrogen generator eliminates the need for conventional electrolyzers. HyperSolar has its corporate headquarters in Santa Barbara, California.
 
Hydrogen fuel usage produces pure water as the only by-product. Through optimizing the science of water electrolysis at the nano-level, HyperSolar’s low cost nanoparticles mimic photosynthesis to efficiently use sunlight to separate hydrogen from water, to produce environmentally friendly renewable hydrogen. The Company’s research focuses on developing a low-cost and submersible hydrogen production particle that can split water molecules under the sun, imitating the central functions of photosynthesis. Each particle is a complete hydrogen generator that contains a novel high voltage solar cell bonded to chemical catalysts by a proprietary encapsulation coating.

HyperSolar H2Generator™ Panels can be connected together to scale to any size system to meet application specific hydrogen requirements. HyperSolar’s intention, using its low cost method to produce renewable hydrogen, is to enable a world of distributed hydrogen production for renewable electricity and hydrogen fuel cell vehicles.

HyperSolar announced in February 2014 that its artificial photosynthesis technology can now produce 1.2 volt open circuit voltage for use in direct solar hydrogen production. This achievement represents another 10 percent increase over the previous 1.1 volt reached late in 2013. 

In March, HyperSolar announced that it jointly filed a patent application with the University of California, Santa Barbara (UCSB) for the "method of manufacture of multi-junction artificial photosynthetic cells." The patent application claims a novel low cost and high voltage multi-junction solar cell made from a single material. The single material has a low cost per watt. The voltage achieved so far in the laboratory is very close to the critical 1.5 volts needed for splitting water molecules into hydrogen and oxygen. 

Recently, HyperSolar announced that it extended its sponsored research agreement with the University of California, Santa Barbara (UCSB) through December 31, 2014, in the continuous pursuit of attaining important milestones in its development plan.

HyperSolar, Inc. (HYSR), closed Wednesday's trading session at $0.034, up 5.92%, on 817,057 volume with 63 trades. The average volume for the last 60 days is 17,490,226 and the stock's 52-week low/high is $0.0035/$0.1345.

EHouse Global, Inc. (EHOS)

Shiznit Stocks, Stocks To Watch, PennyStocks24, Penny Stock Newsletter, Penny Picks, Damn Good Penny Picks, Pumps and Dumps, and Trading Wall St reported earlier on EHouse Global, Inc. (EHOS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Bulletin Board, EHouse Global, Inc. is an emerging specialty nutraceutical company in the dietary supplement industry. The Company is a global holding company looking for business investments in local and international markets. EHouse acquires, develops, and sells innovative consumer oriented products ready for fast commercialization. Through its wholly owned subsidiary, NutraLiquids, LLC, EHouse Global’s launch includes 16 different liquid nutritional products in single serving pouches with some products also available in 30 day supply, 30 ounce bottles.  EHouse Global is based in La Jolla, California.

EHouse Global acquired the shares of NutraLiquids in July of 2013. NutraLiquids develops nutraceutical vitamin, supplement and functional beverage products for the consumer packaged goods industry. It develops unique products based on natural ingredients with leading-edge packaging for the general retail market.

A substantial amount of EHouse Global’s resources are dedicated to research and development (R&D). The Company has created an extensive assortment of popular product segments for the large and growing nutrition industry. These segments include Immunity Support, Weight loss, Omega 3 Heart Health, Detox, Energy, Sleep, Joint Support, Bone Health, Daily Vitamins, and Hangover Prevention. Each of the Company’s products is gluten-free. They are loaded with vitamins, nutrients, as well as natural ingredients.

Regarding production, EHouse Global has been working with a new product formulator with the niche capability to produce the Company's products in large scale "totes." This will permit mass production and inventory building in anticipation of larger purchase orders. Beforehand, EHouse Global was depending on one supplier to produce single "pouches" and "bottles."

Pertaining to marketing, EHouse Global Chief Executive Officer, Mr. Scott Corlett, has been developing the list of potential retailers for the Company's products. Once the production and operations process is perfected, Company management’s intention is to set out on a U.S. wide sales and marketing roadshow. The goal is to secure a number of test orders with national retail chains.

EHouse Global, Inc. (EHOS), closed Wednesday's trading session at $0.0025, down 24.24%, on 12,370,601 volume with 57 trades. The average volume for the last 60 days is 5,763,730 and the stock's 52-week low/high is $0.003/$0.34.

Double Crown Resources, Inc. (DDCC)

WallstreetSurfers reported earlier on Double Crown Resources, Inc. (DDCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed Double Crown Resources, Inc.is a natural resource exploration and development company. Energy resource projects, especially in the petroleum industry, are the chief focus of Double Crown’s efforts and operations. The original business plan of Double Crown Resources was based on the development of mineral mining projects for gold, silver, nickel, and other precious metals. Founded in 2006, Double Crown Resources has its corporate head office in Henderson, Nevada.
 
The Company has a 100 percent interest in the Bateman gold & nickel prospect near Thunder Bay, Ontario. This area is known as The Shebandowan Belt. It has become a prolific gold play. First-rate infrastructure makes Bateman a low cost exploration project. Furthermore, Double Crown is targeting new properties and oilfield supply & service projects, which have the potential for near-term positive cash flow. The Company is currently reviewing numerous new natural resource properties that are near to, or in production, situated in North, South and Latin America. Multiple oilfield service projects are now under active development.

Double Crown Resources has formed a new contractual strategic alliance with Logistica US Terminals, LLC, a subsidiary of Logistica Integral en Transportacion S.A de C.V. to allow for fulfillment of multiple high-value oilfield service projects now in late stage development. As previously announced by Double Crown, Logistica US will provide large quantities of key minerals and related materials needed by oilfield drillers for both on-shore and off-shore operations.

Double Crown Resources announced in February 2014 that its first purchase order was received for supply of the strategic mineral barite. This represents Double Crown’s first revenue generation from its main business plan of oilfield supply and services. Barite is a key commodity required for hydraulic fracturing in oilfield drilling operations.

The Company reported last week that an agreement has been reached granting it rights to all barite ore from the Bilojom II barite mine in Guatemala. Under terms of the agreement, Double Crown will partner with the mine’s original owner, Mr. Jorge Luis Avalos and his company, Geominas S.A. de CV, which is well established in Guatemala.

Double Crown Chief Operating Officer, Mr. Antonio B. Castillo, said, "We have been working for over a year's time to bring the valuable mineral resources of Guatemala into our package of available assets for oilfield drilling customers. The barite from Guatemala is some of the best quality in the world and we will now have exclusive rights to 100% of the ore from the Bilojom II mining operation for this mineral in Guatemala. “

Double Crown Resources, Inc. (DDCC), closed Wednesday's trading session at $0.0169, up 4.32%, on 4,000 volume with 2 trades. The average volume for the last 60 days is 566,279 and the stock's 52-week low/high is $0.0081/$0.045.

Bioheart, Inc. (BHRT)

Investor News Source, AwesomePennyPicks, Vantage Wire, PennyTrader Publisher, Pumps and Dumps, Premium Stock Picks, and Pick Alerts reported previously on Bioheart, Inc. (BHRT), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Sunrise, Florida, Bioheart, Inc.’s dedication is to maintaining its leading position within the cardiovascular sector of the cell technology industry. The Company delivers cell therapies and biologics. These help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, and other issues. Its lead product is MyoCell®. Bioheart’s shares trade on the OTC Markets’ OTCQB.

The Company’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations. Regarding biotechnology, Bioheart is concentrating on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its MyoCell® product is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells to improve cardiac function in chronic heart failure patients. 

The Company’s MyoCell® therapy consists of myoblasts that are injected into the scar tissue, which has formed in the hearts of patients suffering from heart failure. The increased muscle formed by MyoCell® in these patients’ hearts has been shown to lead to improved cardiac function and an improved quality of life.

Earlier this month, Bioheart announced an update on the phase I safety trial using adipose derived cells. The Company’s AdipoCell™ product is presently undergoing study in an array of indications. These include erectile dysfunction, chronic obstructive pulmonary disease and dry macular degeneration. Approximately four years ago, Bioheart began a study using adipose derived stem cells (AdipoCell™) in congestive heart failure patients. The patients were recently contacted to assess quality of life. The patients reported that they are in good spirits and doing well. 

Last week, Bioheart announced its financial results for the first quarter of 2014. Product revenues during the first quarter of 2014 were $322,572, versus $4,192 during Q1 2013. Furthermore, this represents a 98 percent increase over the fourth quarter revenue of $157,055. 

Bioheart, Inc. (BHRT), closed Wednesday's trading session at $0.024, up 17.65%, on 2,099,648 volume with 93 trades. The average volume for the last 60 days is 3,369,250 and the stock's 52-week low/high is $0.0063/$0.08.

Aethlon Medical, Inc. (AEMD)

StockBlogs reported recently on Aethlon Medical, Inc. (AEMD), Streetwise Reports, BestStockChoice, and PennyStocks24 did earlier, and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTC Bulletin Board-listed Aethlon Medical, Inc.'s mission is to create novel medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Its Aethlon ADAPT™ System (Adaptive Dialysis-Like Affinity Platform Technology) is a revenue-stage technology platform. This system provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. Aethlon Medical has its headquarters in San Diego, California.

In September 2013, Aethlon Medical announced the formal launch of Exosome Sciences, Inc. (ESI). This is its majority-owned subsidiary earlier established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease, and other life-threatening conditions.

The Aethlon ADAPT™ System is a medical device platform that joins single or multiple affinity drug agents with advanced plasma membrane technology. This is to create therapeutic filtration devices that selectively remove harmful particles from the entire circulatory system without the loss of essential blood components. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer. Aethlon Medical’s Aethlon Hemopurifier® is a first-in-class medical device with wide-spectrum capabilities against viral pathogens. These include the human immunodeficiency virus (HIV), hepatitis C virus (HCV), and many bioterror and pandemic threats. 

Aethlon Medical also has its ELLSA™ Exosome Assay. This is an enzyme-linked lectin-specific assay that has demonstrated the ability to identify and quantify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and all forms of cancer tested to date. The Company’s pipeline also includes a medical device undergoing development under a five-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers (DARPA Sepsis Program). Additionally, Aethlon has its HER2osome™. It provides a therapeutic strategy to maximize the ability of the immune system and established drug therapies to combat HER2+ breast cancer.

Today, Aethlon Medical announced high rapid virologic response (RVR) and sustained virologic response (SVR) rates in Hepatitis-C virus (HCV) infected individuals who were administered Hemopurifier® therapy. The Company recently related that the United States Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE), which now allows Aethlon to initiate HCV human feasibility studies of Hemopurifier® therapy in the U.S.  Aethlon announced yesterday that its first U.S. clinical study will take place at the DaVita MedCenter Dialysis in Houston, Texas. 

Aethlon Medical, Inc. (AEMD), closed Wednesday's trading session at $0.205, up 11.41%, on 717,657 volume with 110 trades. The average volume for the last 60 days is 402,920 and the stock's 52-week low/high is $0.084/$0.293.

graphic

The QualityStocks
Company Corner

graphic
graphic

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.43, up 7.47%, on 150 volume with 1 trades. The stock’s average daily volume over the past 60 days is 17,455, and its 52-week low/high is $0.284/$1.00.

Zenosense, Inc. was pleased to announce that based on data and information provided by and reviews with Zenon Biosystem considerable progress has been made since signing the development agreement six months ago. Development of the Company's MRSA device commenced in December, 2013 and a technical review of Volatile Organic Compounds produced by Methicillin-susceptible S.aureus and MRSA in vitro or exhaled breath was undertaken.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc. Provides Development Update

Zenosense, Inc. Extends License to Include Cancer Applications

Zenosense, Inc. Enters Into $475,000 Securities Purchase Agreement

Armco Metals Holdings, Inc. (AMCO)

The QualityStocks Daily Newsletter would like to spotlight Armco Metals Holdings, Inc. (AMCO). Today, Armco Metals Holdings, Inc. closed trading at $0.2252, up 4.74%, on 164,006 volume with 125 trades. The stock’s average daily volume over the past 60 days is 555,382, and its 52-week low/high is $0.20/$0.58.

Armco Metals Holdings, Inc. today announced that the Company has received a credit approval letter from a Chinese commercial bank with an approved credit limit equivalent to RMB 96 million or $15 million, of which $7.5 million can be used for general purposes such as Import Letters of Credit and Import Bill Advances, and the other $7.5 million can be used for special business purposes such as secured business loans. The new credit facility became effective on May 16, 2014 and is in effect for a period of 12 months and replaced the facility of RMB 78 million or $12.7 million we had with the same bank.

Armco Metals Holdings, Inc. (AMCO), since its founding 10 years ago, has worked tirelessly to create low-cost, high-quality solutions to meet steel industry demands and achieve its goal to become the largest scrap steel recycler in China. The company operates through five subsidiaries located in key regions throughout the country to source, import, process, and distribute quality, environmentally friendly recycled scrap steel, as well as metal and non-ferrous metal ore.

Subsidiaries Armco Metals International, Ltd., Armco (Lianyungang) Renewable Metals, Inc., Armet (Lianyungang) Holdings, Inc., Henan Armco & Metawise Trading Co., Ltd., Armco Metals (Shanghai) Holding, Ltd. support Armco Metal’s overarching corporate mission and operate to provide the country’s steel production industry with sustainable, responsible solutions to its material needs. Aligned with China’s green initiatives, Armco Metals and its subsidiaries are helping the government reach its scrap metal consumption goal of 20% by 2015.

Leveraging long-standing relationships with more than 10 international metal suppliers, more than 100 small- and medium-sized Chinese steel production companies, and some of the country’s large state-run foundries, Armco Metals benefits from a steady and dependable supply of demand for the company’s high-quality product known for excellent market values.

Armco Metals’ management team has established a unique approach to business and environment by providing responsible solutions based on environmentally friendly practices; reliable, cost-effective sourcing; and quality metal products. Backed by more than 10 years of industry experience, company executives have successfully positioned the company as credible, dependable partner for customers, suppliers, and investors within the steel production market. Disclaimer

Armco Metals Holdings, Inc. Company Blog

Armco Metals Holdings, Inc. News:

Armco Metals Holdings, Inc. Receives $15 Million Credit Approval From a Chinese Commercial Bank

Armco Metals Holdings Announces Financial Results for the First Quarter of 2014

Armco Metals Holdings Enters Into Scrap Steel Distribution Agreement With TEWOO Metals International Trade Co., Ltd.

Well Power Inc. (WPWR)

The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.19, up 65.22%, on 5,002,659 volume with 722 trades. The stock’s average daily volume over the past 60 days is 685,778, and its 52-week low/high is $0.005/$2.00.

Well Power Inc. (WPWR) has secured the US licensing rights to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and dilents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.

The company is able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.

Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.

Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer

Well Power Inc. Company Blog

Well Power Inc. News:

Well Power Inc. Information to be Available through S&P Capital IQ Corporation Records Program

Flaring continues to be a problem - Well Power Inc. plans negotiations with MEC to acquire additional territories

Well Power Inc. corporate update

Innocent, Inc. (INCT)

The QualityStocks Daily Newsletter would like to spotlight Innocent, Inc. (INCT). Today, Innocent, Inc. closed trading at $0.011, up 57.14%, on 37,300 volume with 3 trades. The stock’s average daily volume over the past 60 days is 8,560, and its 52-week low/high is $0.0005/$0.092.

Innocent, Inc. (INCT) is a development stage oil and gas exploration and production company focused on developing properties in North America. The company plans to minimize the risk of exploration through development of proved petroleum reserves, and expects to maximize profit through strategic acquisition and liquidation of selected oil and gas properties.

The company specializes in acquiring low risk, high upside properties with substantial exploration potential. Through improvements in oil and gas production technologies, Innocent aims to rapidly increase production levels and generate predictable, sustainable value. The business strategy utilized calls for both 100% acquisitions and joint-ventures to maximize production capacity.

Evergreen Petroleum, a joint venture partner, is working closely with the company to explore oil-bearing formations in Wyoming. Evergreen has conducted and will continue to conduct both regional and local geological studies to define prospects that are worthy of acquiring oil and gas leases. By partnering with industry experts such as Evergreen, Innocent has strategically added extensive technical guidance and field management experience.

Even during challenging times, the world depends on oil & gas exploration and production companies to deliver millions of barrels of oil every day. Increased demand from emerging countries such as China further escalates competition for this precious resource. Backed by an experienced group of professionals, Innocent is well positioned to generate substantial revenues in the short and long term future. Disclaimer

Innocent, Inc. Company Blog

Innocent, Inc. News:

Innocent Inc. Announces Letter to Shareholders

Innocent Inc. Announces New Joint Venture to Explore for Oil and Gas

Innocent, Inc. (INCT) is "One to Watch"

Ecrypt Technologies, Inc. (ECRY)

The QualityStocks Daily Newsletter would like to spotlight Ecrypt Technologies, Inc. (ECRY). Today, Ecrypt Technologies, Inc. closed trading at $0.128, up 3.23%, on 8,344 volume with 2 trades. The stock’s average daily volume over the past 60 days is 6,799 and its 52-week low/high is $0.055/$0.28.

Ecrypt Technologies, Inc. (ECRY) is an emerging provider of military-strength data security solutions for enterprise, government, and military. The company empowers organizations with the freedom to communicate and collaborate without risk of liability, reputation damage, competitive threat, and other negative outcomes. Ecrypt is the trusted first choice for those looking to keep their communications confidential.

Today’s businesses struggle to guard against the increasing number of dangers as a result of complicated networks built with many different components that are often individually patched to address new threats, while neglecting to close security gaps in traditional solutions. On average, data breaches and subsequent fines and litigation cost a US business $534 million every year, the highest in the world according to the Ponemon Institute.

The flagship Ecrypt solution is an integrated email and encryption server that can be quickly deployed to fortify the security of corporate communication, including attachments and mobile devices, against data breaches while eliminating phishing threats, malware infections, and spam. By using Ecrypt’s paradigm-shifting technology, companies alleviate the need for separate encryption servers with their associated bloated administration and multiple points of weakness.

Ecrypt is well positioned to benefit from increasingly demanding data confidentiality regulations such as the Health Insurance Portability and Accountability Act (HIPAA), the Federal Information Security Management Act (FISMA), and Gramm-Leach-Bliley Act (GLBA). As a result of extensive market research and working directly with organizations in multi-billion dollar industries, the company fully understands the business community’s need to maintain confidentiality, prevent data breaches, comply with government regulations, and mitigate litigation risks. Disclaimer

Ecrypt Technologies, Inc. Blog

Ecrypt Technologies, Inc. News:

Ecrypt Technologies Appoints Former Microsoft Engineer to Advisory Board

Ecrypt Technologies Forms Advisory Board

Ecrypt Technologies, Inc. Commences Development of a Product Sandbox

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Real Pennies
(CAPA)

2.

TheMicrocapNews
(CLNP)

3.

QualityStocks
(WPWR)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251